sorafenib has been researched along with ku 55933 in 1 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (ku 55933) | Trials (ku 55933) | Recent Studies (post-2010) (ku 55933) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 164 | 0 | 127 |
Protein | Taxonomy | sorafenib (IC50) | ku 55933 (IC50) |
---|---|---|---|
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Homo sapiens (human) | 0.458 | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Homo sapiens (human) | 0.133 | |
Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 7.44 | |
DNA-dependent protein kinase catalytic subunit | Homo sapiens (human) | 1.4943 | |
Serine-protein kinase ATM | Homo sapiens (human) | 0.191 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Knight, ZA; Shokat, KM | 1 |
1 review(s) available for sorafenib and ku 55933
Article | Year |
---|---|
Features of selective kinase inhibitors.
Topics: Animals; Drug Evaluation, Preclinical; Humans; Phosphoric Monoester Hydrolases; Protein Kinase Inhibitors; Substrate Specificity | 2005 |